then the goal would be to combine them with GLP-1 agonist GSBR-1290 to treat patients with obesity. The third risk to consider would be in terms of competition in the obesity space. For instance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback